{
    "body": "What is the clinical value of MammaPrint?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20975745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18159035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19825882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19214742"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7746488", 
            "o": "Clinic"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A8316941", 
            "o": "Clinical"
        }
    ], 
    "ideal_answer": [
        "MammaPrint has a prognostic value for distant metastasis and death, as well as predictive value for response to adjuvant chemotherapy in patients with breast cancer. However, the EGAPP Working Group found no evidence regarding the clinical utility of the MammaPrint."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013677", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003695", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008495", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015510", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019411"
    ], 
    "type": "summary", 
    "id": "51485b9ad24251bc0500002b", 
    "snippets": [
        {
            "offsetInBeginSection": 1118, 
            "offsetInEndSection": 1280, 
            "text": "In the intermediate-risk subgroup, the 70-gene signature could be useful to decide in elderly patients whether they may benefit from adjuvant chemotherapy or not.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 209, 
            "offsetInEndSection": 401, 
            "text": "Adjuvant assessment tools for prognosis and prediction of treatment benefit, including Adjuvant! Online, the St Gallen Consensus, Oncotype DX(\u00ae) and MammaPrint(\u00ae), aid clinical decision making", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975745", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1108, 
            "offsetInEndSection": 1368, 
            "text": "The 70-gene MammaPrint prognosis profile accurately identified Japanese breast cancer patients at low risk of developing recurrences. In fact, 100% of the individuals in the low-risk category remained metastasis-free for the duration of the observation period.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 965, 
            "offsetInEndSection": 1094, 
            "text": "he probability of distant metastasis-free survival at five years was 100% for the low-risk group and 94% for the high-risk group.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1114, 
            "offsetInEndSection": 1350, 
            "text": "The 70-gene prognosis signature can accurately select postmenopausal patients at low risk of breast cancer-related death within 5 years of diagnosis and can be of clinical use in selecting postmenopausal women for adjuvant chemotherapy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19825882", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 98, 
            "text": "The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 881, 
            "offsetInEndSection": 1036, 
            "text": "A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2090, 
            "offsetInEndSection": 2349, 
            "text": "The EWG found adequate evidence to characterize the association of MammaPrint with future metastases, but inadequate evidence to assess the added value to standard risk stratification, and could not determine the population to which the test would best apply.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2458, 
            "offsetInEndSection": 2665, 
            "text": "he EWG found no evidence regarding the clinical utility of the MammaPrint and Quest H:I Ratio tests, and inadequate evidence regarding Oncotype DX. These technologies have potential for both benefit and harm", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 965, 
            "offsetInEndSection": 1323, 
            "text": "MammaPrint, an oligonucleotide microassay performed on fresh-frozen tumor samples, analyzes the expression of 70 genes. Studies have found that MammaPrint allows young patients (<61 years) with early-stage breast cancer to be categorized as having a high or low risk of distant metastasis. High-risk patients may then be managed with more aggressive therapy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18159035", 
            "endSection": "sections.0"
        }
    ]
}